Abstract:While anticancer drug discovery has seen dramatic innovations and successes, sequential single therapies are time-limited by resistance, and combinatorial strategies have been lagging. The number of possible drug combinations is vast. To select drug combinations the oncologist requires knowledge of the optimal combination of proteins to co-target. Currently, combinations that the oncologist considers are primarily from empirical observations and clinical praxis. Our aim is to develop a signaling-based method to discover optimal proteins for the oncologist to co-target with drug combinations, and test it on available, patient-derived data. To temper the expected resistance to single drug regimen, we offer a concept-based stratified pipeline aimed at selecting co-targets for drug combinations. Our strategy is unique in its co-target selection being based on signaling pathways. This is significant since in cancer, drug resistance commonly bypasses blocked proteins by wielding alternative, or complementary, routes to execute cell proliferation. Our network-informed signaling-based approach harnesses advanced network concepts and metrics, and our compiled, tissue-specific co-existing mutations. Co-existing driver mutations are common in resistance. Thus, to mimic cancer and counter drug resistance scenarios, our pipeline seeks co-targets that when targeted by drug combinations, can shut off cancer's modus operandi. That is, its parallel or complementary signaling pathways would be blocked. Rotating through combinations could further lessen emerging resistance. We applied it to patient-derived breast and colorectal ESR1|PIK3CA and BRAF|PIK3CA subnetworks. Consistently, in breast cancer, our results suggest co-targeting proteins from the ESR1|PIK3CA subnetwork with an alpelisib-LJM716 combination. In colorectal cancer, they co-target BRAF|PIK3CA with alpelisib, cetuximab, and encorafenib combination. Collectively, our pipeline's results are promising, and validated by patient-based xenografts.

Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

Targeting the RAS upstream and downstream signaling pathway for cancer treatment

A patent review of RAF kinase inhibitors (2010-2018).

A Patent Review of RAF Kinase Inhibitors (2010–2018)

Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Recent Development of VEGFR Small Molecule Inhibitors As Anticancer Agents: A Patent Review (2021–2023)

Targeting the EGFR signaling pathway in cancer therapy

Targeting RAF dimers in RAS mutant tumors: From biology to clinic

The current state of the art and future trends in RAS-targeted cancer therapies

An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review

Facts and hopes on RAS inhibitors and cancer immunotherapy

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Targeting KRAS: Crossroads of Signaling and Immune Inhibition

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy

Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy